261780 — CHA Vaccine Research Institute Balance Sheet
0.000.00%
- KR₩75bn
- KR₩54bn
- KR₩371m
Annual balance sheet for CHA Vaccine Research Institute, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 24,827 | 61,550 | 57,763 | 38,896 | 40,107 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 188 | 267 | 608 | 454 | 400 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 25,037 | 61,847 | 58,917 | 42,486 | 44,590 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 587 | 1,032 | 1,543 | 1,644 | 1,120 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 25,747 | 65,313 | 61,069 | 45,119 | 47,248 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,806 | 24,706 | 26,789 | 810 | 9,613 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 24,174 | 25,698 | 27,703 | 9,702 | 19,526 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1,573 | 39,615 | 33,366 | 35,417 | 27,722 |
| Total Liabilities & Shareholders' Equity | 25,747 | 65,313 | 61,069 | 45,119 | 47,248 |
| Total Common Shares Outstanding |